News
How Oral Semaglutide Extends GLP-1 Delivery Into Weight Management
The development of oral semaglutide (for example, oral Wegovy) for weight management matters because it addresses a problem that goes well beyond patient convenience. Injectable incretin therapies, including semaglutide and tirzepatide pens, have dominated the
weight-management category in recent years,...
Business & Industry
Sigma Healthcare Pursues Potential Boots Acquisition Deal
Australia’s Sigma Healthcare has confirmed that it is participating in discussions regarding a possible acquisition of Boots, the UK health and beauty retailer, in a transaction reportedly valued at up to $10 billion. The company acknowledged its interest after...
Business & Industry
MHRA Launches AI Sandbox to Accelerate Drug Development
The Medicines and Healthcare products Regulatory Agency (MHRA) has announced the launch of a new AI Sandbox programme designed to explore how artificial intelligence can strengthen medicines safety, improve risk prediction and support faster development of new treatments. Announced...
Business & Industry
Pfizer’s Hympavzi Wins FDA Expanded Approval for Haemophilia A and B
Pfizer has secured an expanded indication approval from the US Food and Drug Administration (FDA) for Hympavzi (marstacimab-hncq), broadening its use in the treatment of haemophilia A or B. The updated approval extends coverage to patients aged 12 years...
Business & Industry
Incyte Expands Haematology Portfolio with Vega Acquisition
Incyte has agreed to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, in a transaction valued at up to $2bn, reinforcing its presence in haematology with the addition of a late-stage treatment candidate for bleeding disorders. Under the terms...
Business & Industry
GSK Targets Nuvalent in $10.6 Billion Oncology Acquisition
GSK has agreed to acquire Nuvalent in a transaction valued at $10.6 billion, positioning the UK-based pharmaceutical company for its largest acquisition in more than a decade and adding two late-stage lung cancer treatments to its portfolio. Through a...
Business & Industry
Firefly Bio Acquisition Strengthens J&J Cancer Pipeline
Johnson & Johnson (J&J) has entered into a definitive agreement to acquire Firefly Bio for $1bn in cash, a move aimed at expanding its oncology research portfolio through the addition of Firefly Bio’s proprietary Firelink degrader-antibody conjugate (DAC) technology....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read